Partners

Resonance Health is a global leader in Magnetic Resonance Imaging (MRI) related diagnostic technologies to assist in the diagnosis and management of disease in the human body.

Considered one of the most innovative organisations in the healthcare service delivery sector, and with a strong patent protected portfolio in attractive markets, Resonance Health has attracted partners around the world who enjoy a range of benefits exclusive to their organisations. Resonance Health is committed to adding value to business relationships and is actively seeking partners in the pharmaceutical and imaging sectors.

Why partner with Resonance Health?

• | Be amongst the first to market a unique service.
Resonance Health provides FerriScan, the world's first regulated non-invasive test for Liver Iron Concentration. FerriScan is currently being globally commercialised with the technology being set up at existing MRI centres throughout the world. Resonance Health offers partners the opportunity to market this unique service with no requirement for new hardware/software purchase, or any other initial outlay. Ferriscan offers partners the opportunity to broaden their clinician referral base and add to the income stream from MRI machines.

• | Experience added value in research and development.
Resonance Health is forming agreements with phamaceutical companies, providing the FerriScan service for clinical trials and adding value to research and development in treating iron overload disorders. FerriScan enables access to the most accurate, non-invasive technology, which assists in developing new therapies and promotes greater patient compliance.

• | Patented technology and regulatory cleared in attractive markets.
Resonance Health has approved patents protecting its intellectual property assets and has regulatory clearance to operate in markets in the USA, UK and Australia.

• | Gain competitive edge and tap strong market demand.
Resonance Health offers partners an opportunity to meet the strong and growing clinical and patient demand for new non-invasive early diagnosis of iron overload. 11 million people worldwide are affected by iron overload and FerriScan is poised to replace liver biopsy as the new industry 'gold standard'.

• | Partner with an experiened and trusted team.
The Resonance Health management team has vast experience in all facets of commercialisation activites. Many of the team have worked both domestically and internationally to launch and manage products into various markets including the medical market. Our relationship with partners is of the utmost importance to Resonance Health and we work to ensure all needs are met and that communication flows seamlessly between organisations.

• | Share in groundbreaking research and development.
Resonance Health is currently conducting important research into a fibrosis test, which will potentially address a multi-billion dollar market. Partner with Resonance Health to expand your technology platform, advance your service and be first to market with new technology.

John Martyn, Marketing Manager at Dr Jones and the I-Med/MIA Network in Adelaide Australia, explained how partnering Resonance Health has benefited their practice:

"The FerriScan service offers us an excellent opportunity to expand our referral base by developing relationships with specialists such as Gastroenterologists, Physicians and Haematologists. We have been well supported by Resonance Health in marketing this service, and it has the potential to add value to our practice. FerriScan technology has provided us with an opportunity to market a unique service, which is clearly of great interest to the medical community."

Resonance Health has commerical agreements with the following organisations:

DCA - I-Med/MIA
Novartis
Mayne Group
SKG Radiology
SMRI

Resonance Health is also proud to be associated with the Australian Haemochromatosis Society.

For organisations interested in finding out more about becoming a partner, please call Liza Dunne, General Manager on +61 (0) 8 9286 5300 or email info@ferriscan.com.